Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III nivolumab vs chemotherapy in previously treated esophageal squamous cell carcinoma
jRCT2080222974Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Overall survival. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2080222974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222974.